Gilead and Galapagos' much-trumpeted R&D alliance has suffered another setback with the abandonment of ziritaxestat after a late-stage failure in idiopathic pulmonary fibrosis (IPF).
Gilead Sciences’ Kite unit has teamed up with the UK’s Oxford BioTherapeutics (OBT) to develop a new clutch of cell therapy products for solid tumours and blood cancers.
US startup Blue Oak Pharma has joined a lengthening list of companies turning to Exscientia of the UK for its expertise in applying artificial intelligence to drug discovery.
It’s all go in the US telehealth sector, with Alphabet’s Google investing $100 million in Amwell on the same day the Boston-based firm unveiled plans for an initial public offe
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.